Last reviewed 2026-04-21 · How we verify

Acetylcysteine/Doxofylline

Acetylcysteine acts as a mucolytic agent to break down mucus, while doxofylline is a xanthine derivative that acts as a bronchodilator and anti-inflammatory agent.

Acetylcysteine acts as a mucolytic agent to break down mucus, while doxofylline is a xanthine derivative that acts as a bronchodilator and anti-inflammatory agent. Used for Chronic obstructive pulmonary disease (COPD) with excessive mucus production, Acute and chronic bronchitis, Asthma with mucus obstruction.

At a glance

Mechanism of action

Acetylcysteine reduces mucus viscosity by breaking disulfide bonds in mucoproteins, facilitating clearance of respiratory secretions. Doxofylline is a methylxanthine that provides bronchodilation through phosphodiesterase inhibition and has anti-inflammatory properties, making the combination useful for clearing airways and improving respiratory function in conditions with excessive mucus production.

Approved indications

• Chronic obstructive pulmonary disease (COPD) with excessive mucus production
• Acute and chronic bronchitis
• Asthma with mucus obstruction
• Cystic fibrosis

Common side effects

• Gastrointestinal upset
• Nausea
• Headache
• Tachycardia
• Tremor

Key clinical trials

• Efficacy and Safety Study of Acetylcysteine/Doxofylline 1200/400 mg Effervescent Tablet in the Treatment of Moderate-Severe COPD. (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Acetylcysteine/Doxofylline CI brief — competitive landscape report
• Acetylcysteine/Doxofylline updates RSS · CI watch RSS
• Neutec Ar-Ge San ve Tic A.Ş portfolio CI